P&T Motion History ADHD

Drugs reviewed	Motion	Date reviewed	Surveillance accepted as adequate	Reiteration of prior motion	Decision
Amphetamines:	After considering the evidence of safety,	December	Yes	No	Passed
amphetamine	efficacy and special populations for the	11, 2024	Chawla		unanimous
dextroamphetamine	treatment of Attention Deficit Hyperactivity		Barkett		
lisdexamfetamine	Disorder (ADHD), I move that				
methamphetamine	methylphenidate based and amphetamine				
mixed amphetamine salts	based agents of both long and short acting				
	formulations as well as non-stimulants are				
Methylphenidates:	safe and efficacious. A long and short acting				
dexmethylphenidate	formulation of each stimulant should be				
methylphenidate	preferred drugs on the Washington State				
serdexmethylphenidate/	Preferred Drug List. The stimulants listed				
dexmethylphenidate	above shall not be subject to therapeutic				
	interchange on the Washington Preferred				
Off label treatments:	Drug List. Both non-stimulant alpha agonists				
armodafinil*	and at least one non-stimulant, that is not an				
bupropion*	alpha agonist should be included as a				
modafinil*	preferred drug on the Washington State				
	Preferred Drug List.				
Non-Stimulants:					
atomoxetine	Motion: Hudson				
clonidine	2 nd : Taylor				
guanfacine					
viloxazine					
Amphetamines:	After considering the evidence of safety,	February	Yes	Yes	Passed
amphetamine	efficacy and special populations for the	28, 2024	Weiland	Beste	unanimous
dextroamphetamine	treatment of Attention Deficit Hyperactivity		Barkett	Davydow	
lisdexamfetamine	Disorder (ADHD), I move that			-	

BOLD = new this update Grey = part of PDL, not included in update Grey* = not part of PDL

12/11/2024

P&T Motion History ADHD

methamphetamine	methylphenidate based and amphetamine		
mixed amphetamine salts	based agents of both long and short acting		
1	formulations are safe and efficacious. A long		
Methylphenidates:	and short acting formulation of each		
dexmethylphenidate	stimulant should be preferred drugs on the		
methylphenidate	Washington State Preferred Drug List. No		
serdexmethylphenidate/	single stimulant medication is associated		
dexmethylphenidate	with fewer adverse events in special		
	populations. The stimulants listed above		
Off label treatments:	shall not be subject to therapeutic		
armodafinil*	interchange on the Washington Preferred		
bupropion*	Drug List.		
modafinil*			
	After considering the evidence of safety		
Non-Stimulants:	efficacy and special populations for the		
atomoxetine	treatment of Attention Deficit Hyperactivity		
clonidine	Disorder (ADHD), I move that at least one		
guanfacine	non-stimulant, that is not an alpha agonist		
viloxazine	that is safe and efficacious for ADHD,		
	should be included as a preferred drug on the		
	Washington State Preferred Drug List.		
	After considering the evidence of safety		
	efficacy and special populations for the		
	treatment of Attention Deficit Hyperactivity		
	Disorder (ADHD), I move that the alpha agonists clonidine and guanfacine are safe		
	and efficacious and that both of these agents		
	should be included as a preferred drug on the		
	Washington State Preferred Drug List.		
	washington State Freteneu Drug List.		

BOLD = new this update Grey = part of PDL, not included in update Grey* = not part of PDL

12/11/2024

P&T Motion History ADHD

Motion: Beste		
2 nd : Davydow		

BOLD = new this update Grey = part of PDL, not included in update Grey* = not part of PDL

12/11/2024